Navigation Links
New Executive Leadership and CEO Announced for BiPar Sciences

BRIDGEWATER, N.J. and SOUTH SAN FRANCISCO, Calif., Dec. 11 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and its wholly-owned subsidiary, BiPar Sciences, today announced changes to the executive management team at BiPar Sciences.

BiPar Chief Executive Officer and President Hoyoung Huh, M.D., Ph.D. will take on a broader role in the sanofi-aventis organization as Chairman of the Board of Directors of BiPar, as well as chair of the newly formed BiPar Innovation Board. As part of this new role, Dr. Huh will serve as advisor to sanofi-aventis Chief Executive Officer Christopher A. Viehbacher and to Executive Vice President Research and Development Marc Cluzel, as well as to the Executive Committee, in the areas of innovation, R&D transformation, and entrepreneurship.

Sanofi-aventis has appointed Atul Dhir, M.D., Ph.D. as Chief Executive Officer of BiPar Sciences effective December 1, 2009. Dr. Dhir's mission is to continue developing the innovative BiPar portfolio, including the ongoing clinical program of BSI-201 - which, of an emerging class of investigational compounds (PARP inhibitors), is currently the furthest along in the Phase 3 clinical development in the metastatic triple negative breast cancer setting. As new Chief Executive Officer, Dr. Dhir will also be focused on maintaining the autonomy and entrepreneurial culture of BiPar, while capitalizing on the deep resources and experience of the worldwide sanofi-aventis organization.

Prior to joining BiPar, Dr. Dhir was a senior executive at US Oncology, one of the nation's largest cancer treatment and research networks. Previously, he had served as a vice president of the Healthcare Division of Monsanto and a consultant with McKinsey and Company.

About BiPar Sciences

BiPar Sciences is a biopharmaceutical organization dedicated to pioneering novel tumor-selective therapies designed to address urgent unmet needs of cancer patients. In addition to BSI-201, the company also has two additional compounds in preclinical development. BiPar Sciences, located in South San Francisco, California, is an independent, wholly-owned subsidiary of sanofi-aventis, Inc. For more information, please visit

About sanofi-aventis

Sanofi-aventis is a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the lives of patients. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York ( SNY).

Media Contacts:

Salah Mahyaoui
Global Communications
Tel : +33 1 53 77 40 31
Mobile : +33 6 73 68 78 88

Madeline Malia
U.S. Communications
Tel: +1 908 981 5687
Mobile: +1 609 651 1323

SOURCE sanofi-aventis

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
2. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
3. Industry Executives Finding Value in Shift of Scientific Publications
4. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
5. Evalve Expands Executive Leadership Team
6. ParagonRx Names Ellen M. Derrico To Chief Marketing Executive Post
7. Tata Interactive Systems Partners With Bersin & Associates for Exclusive Executive Learning Forum - TLF 2009
8. Premier Research Appoints Troy W. McCall, Ph.D. as Chief Executive Officer
9. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
10. Lincare Holdings Inc. Extends Terms of Employment Agreements with Executive Officers
11. Curemark Announces Senior Executive Promotions
Post Your Comments:
(Date:6/26/2016)... of Australia,s successful biotechnology scientists, Dr ... company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm is ... the ASX. Noxopharm is a clinic-ready company with its ... clinical study later this year. ... facing cancer patients - the ability of cancers to become resistant ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
Breaking Medicine News(10 mins):